RespireRx Pharmaceuticals Inc. to Present at the BIO Investor
Forum on Tuesday, October 18, 2016 at the St. Francis Hotel in San
Francisco, California
GLEN ROCK, NJ-(Marketwired - Oct 17, 2016) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for respiratory disorders,
including drug-induced respiratory depression and sleep apneas,
announced that the Company's President, CEO and Vice Chairman of
the Board of Directors, James S. Manuso, Ph.D., will present at the
BIO Investor Forum on Tuesday, October 18, 2016 at 11:00 A.M.
Pacific Time. The Forum is sponsored by the Biotechnology
Innovation Organization and is scheduled for Tuesday and Wednesday,
October 18 and 19, 2016. Dr. Manuso will be available for
one-on-one meetings with Forum attendees on both days.
Commented Dr. Manuso, "The presentation at the BIO Investor
Forum will allow us to provide investors with an update on
RespireRx's recent reverse stock split, strategic initiatives and
progress on research and development programs. In particular, I
look forward to discussing our clinical progress in developing
novel medicines, including dronabinol, for a variety of respiratory
diseases." Dr. Manuso concluded, "We are pleased to keep our
shareholders and other stakeholders informed as to the continuing
progress of RespireRx's scientific, clinical and regulatory
initiatives."
Dr. Manuso's live presentation and accompanying slides will be
accessible on Tuesday, October 18, 2016 at 11:00 A.M. Pacific Time
(2:00 P.M. Eastern Time) using the following link:
http://www.veracast.com/webcasts/bio/investorforum2016/69113192151.cfm.
The presentation and slides will be accessible after the
presentation by clicking on the same link or on the investors tab
on the RespireRx web-site at www.respirerx.com and following the
links and instructions. A copy of the slide presentation being
presented at the Forum will be submitted in a Form 8-K filing with
the U.S. Securities and Exchange Commission prior to the
presentation.
About RespireRx Pharmaceuticals Inc. RespireRx Pharmaceuticals
Inc. is a leader in the development of medicines for respiratory
disorders, with a focus on drug-induced respiratory depression and
sleep apneas. The Company holds exclusive licenses and owns patents
and patent applications for certain families of chemical compounds
that claim the chemical structures and their uses in the treatment
of a variety of disorders, as well as claims for novel uses of
known drugs.
RespireRx has a pipeline of medicines in Phase 2 clinical
development focused on pharmaceutical treatments for a variety of
different breathing disorders. Clinical development in the area of
respiratory disorders, particularly drug-induced respiratory
depression and sleep apnea, has created opportunities for the
development and commercialization of the Company's compounds.
Cannabinoids. One platform being developed by RespireRx is the
class of compounds known as cannabinoids, including dronabinol.
Under a license agreement with the University of Illinois, the
Company has rights to patents claiming the use of cannabinoids for
the treatment of sleep-related breathing disorders. In a
double-blind, placebo-controlled, dose-ascending Phase 2A clinical
study conducted by the Company, dronabinol produced a statistically
significant reduction in the Apnea-Hypopnea Index, the primary
therapeutic end-point, and was observed to be safe and
well-tolerated in a group of patients with Obstructive Sleep Apnea
("OSA"). The University of Illinois and three other centers
conducted a six week, double-blind, placebo-controlled Phase 2B
clinical trial investigating the effects of dronabinol in patients
with OSA. The University of Illinois has indicated that recruitment
for this clinical trial was completed during the second quarter of
2016. Final research results are expected to be published in the
fourth quarter of 2016. This clinical trial was fully funded by the
National Heart, Lung and Blood Institute of the National Institutes
of Health and is being managed by University of Illinois
researchers.
Ampakines. The other platform of proprietary medicines being
developed by RespireRx are ampakines, which act to enhance the
actions of the excitatory neurotransmitter glutamate at AMPA
glutamate receptors. Several ampakines, in both oral and injectable
forms, are being developed by the Company for the treatment of a
variety of breathing disorders. In clinical studies, select
ampakines have shown preliminary efficacy in central sleep apnea
and in the control of respiratory depression produced by opioids,
without altering the opioid analgesic effects. In animal models of
orphan disorders, such as Pompe Disease, spinal cord injury and
perinatal respiratory distress, it has been demonstrated that
certain ampakines improve breathing function. The Company's
compounds belong to a new class that does not display the
undesirable side effects previously reported for other
ampakines.
During March 2016, a Phase 2A clinical trial at Duke University
School of Medicine was initiated with the Company's proprietary
ampakine, CX1739, to determine the ability of its orally
administered form to prevent the respiratory depression produced by
remifentanil, a potent opioid, without altering remifentanil's
analgesic properties. The dosing portion of the clinical trial was
completed in June 2016 and the clinical trial was formally
completed on July 11, 2016. The Company is working with the Duke
University clinical research team to finalize data analysis and
issue a final report on the results of the clinical trial by the
end of December 2016.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's web-site at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission at www.sec.gov.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and the Company
intends that such forward-looking statements be subject to the safe
harbor created thereby. These might include statements regarding
the Company's financial position, business strategy and other plans
and objectives for future operations, and assumptions and
predictions about research and development efforts, including, but
not limited to, preclinical and clinical research design,
execution, timing, costs and results, future product demand,
supply, manufacturing, costs, marketing and pricing factors, which
are all considered forward-looking statements.
In some cases, forward-looking statements may be identified by
words including "anticipates," "believes," "intends," "estimates,"
"expects," "plans," and similar expressions that include, but are
not limited to, statements regarding (i) future research plans,
expenditures and results, (ii) potential collaborative
arrangements, (iii) the potential utility of the Company's proposed
products, and (iv) the need for, and availability of, additional
financing.
The forward-looking statements included herein are based on
current expectations that involve a number of risks and
uncertainties. These forward-looking statements are based on
assumptions regarding the Company's business and technology, which
involve judgments by management with respect to, among other
things, future scientific, economic and competitive conditions, and
future business decisions, all of which are difficult or impossible
to predict accurately and many of which are beyond the Company's
control. Although the Company believes that the assumptions
underlying the forward-looking statements are reasonable, actual
results may differ materially from those set forth in the
forward-looking statements. In light of the significant
uncertainties inherent in the forward-looking information included
herein, the inclusion of such information should not be regarded as
a representation by the Company or any other person that the
Company's objectives or plans will be achieved.
Factors that could cause or contribute to such differences
include, but are not limited to, regulatory policies or changes
thereto, available cash, pre-clinical and clinical trial results,
competition from other similar businesses, and market and general
economic factors. This press release should be read in conjunction
with the condensed consolidated financial statements (unaudited)
and notes thereto included in Item 1 of the Company's most recently
filed Quarterly Report on Form 10-Q and the Company's Annual Report
on Form 10-K for the fiscal year ended December 31, 2015, including
the section entitled "Item 1A. Risk Factors." The Company does not
intend to update or revise any forward-looking statements to
reflect new information, future events or otherwise.
Contact Information
- Company Contact:
- Jeff Margolis
- Vice-President, Treasurer and Secretary
- Telephone: (917) 834-7206
- E-mail: jmargolis@respirerx.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024